Jubilant Ingrevia Q1FY27 profit surges 41%, EBITDA guidance held
Jubilant Ingrevia delivered strong Q1FY27 results with net profit rising 41% to ₹106 crore and revenue hitting a 15-quarter high of ₹1,300 crore. Growth was fueled by volume expansion and better pricing in Specialty Chemicals and Nutrition. The company maintained its full-year EBITDA guidance of ₹750-800 crore, citing sequential improvement prospects.
*this image is generated using AI for illustrative purposes only.
Jubilant Ingrevia Limited reported a consolidated net profit of ₹106 crore for the quarter ended June 30, 2026, marking a 41% increase from ₹75 crore in the corresponding period of the previous year. Revenue from operations grew by 25% to ₹1,300 crore, reaching a 15-quarter high, supported by strong volume growth and improved realizations across its Specialty Chemicals and Nutrition segments. The company maintained its full-year EBITDA guidance at ₹750 crore to ₹800 crore, citing steady demand and stronger pricing as key drivers for sequential improvement through FY27.
Q1FY27 Financial Performance
Jubilant Ingrevia delivered broad-based growth during the quarter. EBITDA rose to ₹209 crore from ₹153 crore in the year-ago period, representing a 36% year-on-year increase and a 22% sequential improvement. The EBITDA margin expanded to 16% from 15% year-on-year. Management attributed the strong start to FY27 to disciplined execution, diversified sourcing capabilities that mitigated geopolitical disruptions in the Middle East, and effective cost pass-throughs.
| Metric: | Q1FY27 (₹ in crore) | Q1FY26 (₹ in crore) | YoY Change |
|---|---|---|---|
| Net Profit: | 106 | 75 | +41% |
| Revenue from Operations: | 1,300 | 1,038 | +25% |
| EBITDA: | 209 | 153 | +36% |
| EBITDA Margin: | 16% | 15% | +100 bps |
Segment Highlights
The Specialty Chemicals business delivered revenue of ₹533 crore, up 11% year-on-year and 3% sequentially. This growth was driven by robust performance in Fine Chemicals and CDMO businesses, with EBITDA standing at ₹139 crore and margins at 26%. The CDMO pipeline has expanded to over 100 molecules with a peak revenue potential exceeding ₹3,500 crore, including 25 confirmed molecules. Five new molecules were added in the last quarter across pharma, semiconductors, and personal care.
The Nutrition & Health segment saw revenue grow to ₹243 crore, up 36% year-on-year. It achieved its highest EBITDA in three years at ₹36 crore, reflecting a 45% year-on-year increase. Niacinamide volumes grew steadily, supported by strong pricing in food and cosmetics applications. The new Niacinamide plant is currently operating at 50% capacity, with management targeting utilization of over 70% by year-end.
Chemical Intermediates experienced a strong rebound with revenue growing to ₹524 crore, up 38% year-on-year. EBITDA for this segment stood at ₹57 crore, up 240% year-on-year, driven by robust demand and price escalations linked to higher input costs.
Outlook and Guidance
Management expects revenue and EBITDA to improve sequentially in FY27. The company has kept its full-year EBITDA guidance unchanged at ₹750 crore to ₹800 crore. Specialty Chemicals and Nutrition projects are expected to collectively account for 70% to 80% of total EBITDA, while the Chemical Intermediates segment is anticipated to generate approximately ₹100 crore annually. The new multipurpose plant remains on track for commissioning by the end of the current calendar year.
Compliance and Investor Communication
The unaudited standalone and consolidated financial results were approved by the Board of Directors at a meeting held on July 22, 2026. Walker Chandiok & Co LLP, the statutory auditors, issued a limited review report confirming compliance with regulatory requirements. The transcript of the investor conference call held on July 23, 2026, was disclosed pursuant to Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015. Deepanjali Gulati, Company Secretary & Compliance Officer, signed the disclosure letter dated July 27, 2026.
Historical Stock Returns for Jubilant Ingrevia
| 1 Day | 5 Days | 1 Month | 6 Months | 1 Year | 5 Years |
|---|---|---|---|---|---|
| -0.29% | -1.50% | -1.13% | +15.50% | +3.30% | -0.06% |
How might the commissioning of the new multipurpose plant by year-end impact Jubilant Ingrevia's capacity utilization and cost structure in FY28?
What are the specific timelines and commercialization risks associated with scaling the 25 confirmed molecules in the CDMO pipeline to their peak revenue potential?
Could geopolitical shifts or supply chain disruptions in the Middle East pose renewed risks to the diversified sourcing strategy that mitigated recent challenges?
20
Create Custom Screeners 
Access 200+ Pre-built Filters 
Use 50+ Readymade Screener 
